1921
Volume 97, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Antiretroviral treatment (ART) interruptions increase the risk of severe morbidity/mortality in human immunodeficiency virus (HIV)-infected individuals from subSaharan Africa. We aimed to determine whether the risk is further increased among HIV–hepatitis B virus (HBV) co-infected patients in this setting. In this sub-analysis of a randomized-control trial, 632 participants from Côte d’Ivoire randomized to receive continuous-ART (C-ART), structured ART interruptions of 2-months off, 4-months on (2/4-ART), and CD4-guided ART interruptions (CD4GT, interruption at 350/mm and reintroduction at 250/mm) were analyzed. Incidence rates (IR) of serious HIV- and non-HIV-related morbidity were compared between patients stratified on hepatitis B surface antigen (HBsAg) status. Overall, 65 (10.3%) were HBsAg-positive, 29 (44.6%) of whom had HBV-DNA levels > 10,000 copies/mL. After a median 2.0 year (range = 0.2–3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV–HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, = 0.3), whereas the highest incidence was observed in co-infected patients with baseline HBV-replication > 10,000 copies/mL (IR = 24.0/100 person/years, versus HIV mono-infected = 0.002). Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, = 0.001). The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups ( for interaction = 0.4). No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients ( = 0.5), even at HBV-replication levels > 10,000 copies/mL ( = 0.7). In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.16-1016
2017-12-06
2019-02-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/97/6/tpmd161016.html?itemId=/content/journals/10.4269/ajtmh.16-1016&mimeType=html&fmt=ahah

References

  1. Danel C, Trivacan ANRS 1269 Trial Group.; , 2006. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 367: 19811989. [Google Scholar]
  2. Danel C, Trivacan ANRS 1269 Trial Group.; , 2009. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J Infect Dis 199: 6676. [Google Scholar]
  3. Ananworanich J, Staccato Study Group Swiss HIV Cohort Study.; ; , 2006. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 368: 459465. [Google Scholar]
  4. El-Sadr WM, Strategies for Management of Antiretroviral Therapy (SMART) Study Group.; , 2006. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 22832296. [Google Scholar]
  5. Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL, , 2012. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 55: 507513. [Google Scholar]
  6. Kouamé GM, 2017. Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication. Clin Infect Dis, 10.1093/cid/cix747. [Google Scholar]
  7. Piroth L, GERMIVIC Study Group.; , 2010. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol 53: 10061012. [Google Scholar]
  8. Piroth L, GERMIVIC Study Group.; , 2015. Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study. Liver Int 35: 19501958. [Google Scholar]
  9. Tedaldi E, SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT).; , 2008. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 47: 14681475. [Google Scholar]
  10. Dore GJ, SMART INSIGHT Study Group.; , 2010. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 24: 857865. [Google Scholar]
  11. Matthews PC, Geretti AM, Goulder PJR, Klenerman P, , 2014. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol 61: 2033. [Google Scholar]
  12. Hoffmann CJ, Thio CL, , 2007. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7: 402409. [Google Scholar]
  13. Boyd A, ANRS 12240 VarBVA Study.; , 2015. Identifying patients infected with hepatitis B virus in Sub-Saharan Africa: potential for misclassification. Diagn Microbiol Infect Dis 83: 248251. [Google Scholar]
  14. Boyd A, ANRS 12240 VarBVA Study.; . 2015. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d’Ivoire. Antivir Ther 20: 643654. [Google Scholar]
  15. Rouet F, 2005. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 43: 27092717. [Google Scholar]
  16. Velen K, Charalambous S, Innes C, Churchyard GJ, Hoffmann CJ, , 2016. Chronic hepatitis B increases mortality and complexity among HIV-coinfected patients in South Africa: a cohort study. HIV Med 17: 702707. [Google Scholar]
  17. Hammer SM, International AIDS Society-USA.; . 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300: 555570. [Google Scholar]
  18. Anglaret X, ANRS 12222 Morbidity/Mortality Study Group.; , 2012. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d’Ivoire. Clin Infect Dis 54: 714723. [Google Scholar]
  19. Nahon P, ANRS CO12 CirVir and Microcir Groups.; . 2017. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut 66: 330341. [Google Scholar]
  20. Chun HM, Infectious Disease Clinical Research Program HIV Working Group , 2012. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 205: 185193. [Google Scholar]
  21. Matthews GV, PHIDISA II Study Team.; , 2011 Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 25: 17271735. [Google Scholar]
  22. Sarfo FS, Kasim A, Phillips R, Geretti AM, Chadwick DR, , 2014. Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana. J Infect 69: 481489. [Google Scholar]
  23. Hawkins C, Christian B, Ye J, Nagu T, Aris E, Chalamilla G, Spiegelman D, Mugusi F, Mehta S, Fawzi W, , 2013. Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania. AIDS 27: 919927. [Google Scholar]
  24. Chen C-J, Yang H-I, Iloeje UH, REVEAL-HBV Study Group; , 2009. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49 (Suppl 5): S72S84. [Google Scholar]
  25. Moh R, 2007. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 21: 24832491. [Google Scholar]
  26. Smith C, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.; , 2010. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 24: 15371548. [Google Scholar]
  27. Riou J, Aït Ahmed M, Blake A, Vozlinsky S, Brichler S, Eholié S, Boëlle P-Y, Fontanet A, HCV Epidemiology in Africa Group; , 2016. Hepatitis C virus seroprevalence in adults in Africa: a systematic review and meta-analysis. J Viral Hepat 23: 244255. [Google Scholar]
  28. Wandeler G, Swiss HIV Cohort Study.; , 2013. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis 208: 14541458. [Google Scholar]
  29. Matthews GV, 2013. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 56: e87e94. [Google Scholar]
  30. Boyd A, Gozlan J, Maylin S, Delaugerre C, Peytavin G, Girard P-M, Zoulim F, Lacombe K, , 2014. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology 60: 497507. [Google Scholar]
  31. Boyer S, Clerc I, Bonono C-R, Marcellin F, Bilé P-C, Ventelou B, , 2011. Non-adherence to antiretroviral treatment and unplanned treatment interruption among people living with HIV/AIDS in Cameroon: individual and healthcare supply-related factors. Soc Sci Med 72: 13831392. [Google Scholar]
  32. Auld AF, 2014. Antiretroviral therapy enrollment characteristics and outcomes among HIV-infected adolescents and young adults compared with older adults--seven African countries, 2004–2013. MMWR Morb Mortal Wkly Rep 63: 10971103. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-1016
Loading
/content/journals/10.4269/ajtmh.16-1016
Loading

Data & Media loading...

Supplemental Table

  • Received : 23 Dec 2016
  • Accepted : 19 Aug 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error